Visible Alpha, a financial technology company that improves the investment research process by capturing value from sell-side analyst models, research reports and corporate access events, announced the launch of Visible Alpha BioPharma , its newest platform for data and detailed financial information.
The rapidly evolving pharmaceutical and biotechnology industries drive constant innovation and the demand for accurate and holistic drug-level predictions is greater than ever before. This demand is further exacerbated by changing regulations, varying clinical trial results and frequent market fluctuations.
With the launch of Visible Alpha BioPharma, Visible Alpha offers investment professionals and drug developers a one-stop shop for comprehensive drug data and detailed financial information. This allows them to quickly identify new opportunities, evaluate market competitiveness, gauge market expectations, analyze historical data, access forward-looking estimates and perform rapid drug-level analysis.
Visible Alpha’s new BioPharma platform enables investment, securities research and drug development professionals to:
- Understand market trends, investor sentiment and evolving drug performance forecasts using detailed financial data.
- Dive deep into drug financials with granular consensus estimates for items like “sales by indication” or “number of patients that can be served.”
- Understand evolving market expectations by analyzing forecasts for specific drugs or grouping drugs by indication, MOA or therapeutic area.
- Accelerate drug performance modeling with immediate access to consensus forecasting and tools like peak sales analytics.
- Search a comprehensive collection of metadata about drugs in the market and in the pipeline to quickly understand the competitive landscape.
- Expand the forecast horizon for long-term revenue forecasts to analyze early-stage drugs in greater detail.
- Generate and refine ideas, gain deep insights into the competitive landscape and drive market forecast analysis and forward-looking information for corporate and investor relations teams.
“According to the FDA, we are seeing a faster pace of innovation and development and more drug approvals in the pharmaceutical and biotechnology industries,” said Mark Hale , CEO of Visible Alpha. “With the creation of Visible Alpha’s BioPharma platform, we are providing investment professionals with the ability not only to monitor drug development, but also to accelerate strategic investment decisions with detailed financial information across thousands of medicines through an interactive platform that enables research and discovery. We are excited to offer our customers this incredibly robust and versatile platform.”
SOURCE: PRNewswire